Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca’s MedImmune completes Amplimmune takeover

AstraZeneca’s MedImmune completes Amplimmune takeover

7th October 2013

AstraZeneca has announced that its global biologics research and development business MedImmune has completed its acquisition of Amplimmune.

Originally agreed in August 2013, the deal saw MedImmune acquire 100 per cent of Amplimmune's shares for an initial consideration of $225 million (140.08 million pounds), plus a deferred consideration of up to $275 million based on predetermined development milestones.

The deal bolsters MedImmune's oncology pipeline thanks to Amplimmune's status as a specialist developer of novel therapeutics in cancer immunology, with multiple early-stage assets in the field of immune-mediated cancer therapy.

These include AMP-514, an anti-programmed cell death 1 monoclonal antibody, as well as several preclinical molecules targeting the B7 pathways.

Amplimmune is building one of the most comprehensive programmes in immune-mediated cancer therapy, treatments which function by empowering the immune system to counteract the tactics employed by cancer cells to avoid detection and attack the body.

Dr Bahija Jallal, executive vice-president for MedImmune, said: "We are excited to be working with the Amplimmune team to help find new treatments to address areas of unmet medical need."ADNFCR-8000103-ID-801646314-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.